Cipla allots 7474 equity shares

"Cipla is our top pick in the sector given high branded generic exposure," UBS said.

Key Indian equity indices -- the BSE Sensex and the NSE Nifty50 -- descended by almost one per cent each during the mid-afternoon trade session on Friday as weak Asian markets, on the back of geo-political risks and depreciation of the rupee subdued ...

Caution over a US Federal Reserve rate-hike in December, coupled with a weak rupee and profit booking by investors, pulled the key Indian equity indices lower to close in the red on Thursday.According to market observers, an upsurge in pharma heavyweights ...

Barring short spells of positivity, the market today traded with distinct weakness for the third day, ending with marginal loss, after the US Fed said it will wind down the stimulus signalling a rate hike this year. The mood at the outset was one of ...

Scrips of Dr Reddy’s, Aurobindo Pharma, Cipla, and Sun Pharma, among others, gained between 2 and 5 percent.

Leading drug maker Cipla Ltd on Friday reported Rs 409 crore consolidated net profit for the first quarter of 2017-18, registering 21 per cent growth from Rs 339 crore in the same period year ago.In a regulatory filing to the BSE, the pharma major said ...

Cipla rose 0.62% to Rs 568 at 12:00 IST on BSE after the company announced the launch of quality-assured Rectal Artesunate Suppositories for severe malaria in young children.

The promoter shareholding is valued at over Rs 16,600 crore

Shares of drug major Cipla today ended over 5 per cent higher after the company reported 23.63 per cent rise in consolidated net profit for the first quarter ended June 30.